Skip to main content

Dermatology

First Look at COVID-19 Global Rheumatology Alliance Registry

Jun 01, 2020

Gianfresco et al have published the first peer-reviewed analysis of COVID-19 infected, rheumatic disease patients entered into the Rheumatology Global Alliance registry; showing that a) rheumatic disease patient can be infected with COVID-19, b) that DMARD and biologic use has no apparent effect

Read Article

RheumNow Podcast - Rheumatic Patients with COVID (5.29.20)

May 29, 2020

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Read Article

Hydroxychloroquine Improves Survival in Lupus

May 26, 2020

Hydroxychloroquine (HCQ) has dominated the news in recent weeks, because of poor outcomes reported when used in COVID patients. Yet, a recent report reaffirms what rheumatologists have known for years - that HCQ use is associated with better outcomes in systemic lupus erythematosus, including

Read Article

Low Risk of COVID-19 Pneumonia in Rheumatic Patients

May 25, 2020

A current letter in the Annals of Rheumatic Disease details the rheumatic disease patient cohort outcomes from the University of Siena, Italy showing only 2 cases of COVID-19 among 859 patients treated with tsDMARDs and bDMARDs.

Read Article

No Certain Link between Biologics and Melanoma Risk

May 21, 2020

A review of available data fails to show an increased risk of melanoma in IMID (inflammatory bowel disease, rheumatoid arthritis, and psoriasis) patients treated with systemic biologic therapies.  



There have been sporadic uncontrolled observational reports suggesting a link between

Read Article

TNR - COVID-Rheumatology Registry & COVID in OZ

May 19, 2020

This week's Tuesday Nite Rheumatology features presentations and interviews with Drs. Peter Nash and Philip Robinson. Dr. Robinson presents latest data on the Rheum-Covid.org Registry, that he helped establish under the Global Rheumatology Alliance. Dr. Nash presents the impact of COVID in

Read Article

Systemic Sclerosis Future Therapies and Outcome Measures

May 19, 2020

Nagaraja, Khanna and colleagues have published an overview of current and future therapies in patients with systemic sclerosis (SSc) and have reviewed the potential outcome measures for this difficult autoimmune disorder. Notably there have been several novel agents studied in recent years,

Read Article

The Nine Lives of Hydroxychloroquine (Updated)

May 18, 2020

Hydroxychloroquine is one of many medications frequently used in rheumatology practice. Its remarkable versatility is attested by its routine use in lupus, in patients with an autoimmune coagulopathy, in patients with rheumatoid arthritis, as well as in those with a low-level inflammatory

Read Article

CDC on Pediatric Multi-System Inflammatory Syndrome

May 14, 2020

The latest hazardous spinoff to the coronavirus infection is an inflammatory, Kawasaki-like syndrome unique to children or adolescents with COVID-19. Sporadic reports from around the globe of this severe pediatric COVID syndrome have littered the news with brief mentions and little detail.

Read Article

Kids' COVID-Linked Ailment Is Not Your Typical Kawasaki Disease

May 14, 2020

As data continue to emerge about a multi-system inflammatory disorder in children apparently connected to COVID-19, evidence is growing that this is not your typical Kawasaki disease.



In New York, up to 102 children have reportedly developed this inflammatory syndrome, and three

Read Article

TNR Grand Rounds - What does COVID-19 have to do with Lupus?

May 13, 2020

Last night's Tuesday Nite Rheumatology featured Dr. Joan Merrill (OMRF). In her lecture, "What does COVID-19 have to do with lupus?", she discusses the pathogenesis of lupus, and specifically thrombotic microangiopathy, complementopathies, catastrophic lupus syndrome and the potential overlap

Read Article

Secukinumab Better than Adalimumab - Maybe?

May 11, 2020

The EXCEED study was a head-to-head trial of secukinumab (SEC) versus adalimumab (ADA) as first-line monotherapy in psoriatic arthritis (PsA) patients; this 52 week trial showed that while SEC failed to achieve clinical superiority over ADA, SEC treated patients demonstrated higher

Read Article

Hydroxychloroquine and QTc Prolongation

May 04, 2020

JAMA Cardiology reports the risk of QT (QTc) prolongation when hydroxychloroquine (HCQ) was given to hospitalized patients with coronavirus disease 2019 (COVID-19), especially when given with azithromycin. 

This single center, cohort study included 90 hospitalized patients with

Read Article

TNR Grand Rounds - Moving Forward with Telemedicine

Apr 22, 2020

Dr. Alvin Wells gives a primer on Telerheumatology and Telemedicine in the era of COVID-19. This 1 hour Grand Rounds Presentation includes a 30 minute lecture, followed by stimulating 30 minutes of Q&A with a rheumatology attendee audience.

Read Article

COVID-19 Systemic Involvement

Apr 15, 2020

The presentations of the COVID-19 infection have been clearly chronicled with the worrisome onset of sore throat, dry cough, loss of smell and taste with fevers, myalgias, fatigue and the worrisome progression of pulmonary involvement in a minority.  Lab findings may include a leukocytosis,

Read Article

Rituximab in Rheumatoid Vasculitis

Apr 15, 2020

The Journal of Rheumatology reports a retrospective, single center, analysis of 17 rheumatoid vasculitis patients who responded well to intravenous rituximab (RTX) therapy.

They identified 17 patients treated with RTX for systemic rheumatoid vasculitis from 2000 to 2017. At RV

Read Article

Post 9/11 Autoimmune Disease Risk

Apr 14, 2020

The 9/11/01 terrorist attach on the World Trade Center (WTC)  resulted in at least 2,977 fatalities, over 25,000 injuries, and caused at least $10 billion in infrastructure and property damage.  Arthritis & Rheumatology reports that dust cloud exposure among responders and PTSD

Read Article

Guselkumab a Hit in Phase III for PsA

Apr 13, 2020

The monoclonal antibody guselkumab (Tremfya), which binds the interleukin (IL)-23 p19 subunit, was effective for psoriatic arthritis in two large clinical trials, providing comprehensive benefits for this heterogeneous disorder, investigators reported in The Lancet.

Read Article

TNR - Grand Rounds: Safety of Biologics & New Agents

Apr 08, 2020

On Tuesday, April 7th, RheumNow hosted its first Tuesday Nite Rheumatology webinar - kicking off a two-month series of Rheumatology Grand Rounds lectures.  The first session featured Jack Cush, MD (UT Southwestern) who lectured on "The Safety of Biologics and Newer Agents".

This 30

Read Article

NICE Guidelines on Managing Rheumatologic Conditions During COVID-19 Pandemic

Apr 07, 2020

On April 3rd, the National Institute for Health and Care Excellence (NICE) in the UK, published a rapid guideline for managing children and adults with rheumatological autoimmune, inflammatory and metabolic bone disorders during the COVID-19 pandemic, while protecting staff from infection.

Read Article

Tofacitinib Effective in Refractory Still's Disease

Feb 20, 2020

Fourteen cases reported from mainland China suggest that tofacitinib (TOFA) may be effective in patients with refractory adult-onset Still’s disease (AOSD), further adding to a growing list of potential use of JAK inhibition in managing inflammatory, and now autoinflammatory, disease.

Read Article

Upadacitinib Effective in Phase 3 Psoriatic Arthritis Study

Feb 07, 2020

Abbvie has announced top line results of their SELECT-PSA trial of upadacitinib (UPA), wherein both the 15 and 30 mg doses met the primary endpoint of ACR20 response at week 12 and demonstrated radiographic inhibition at week 24.

SELECT-PsA 1 was a Phase 3, double-blind, randomized

Read Article

RheumNow Podcast- Best Biologics (2.7.20)

Feb 07, 2020

Dr Jack Cush reviews the news and journal articles from the past week on RheumNow.com

Read Article

Which Biologics are Best in Psoriasis

Feb 05, 2020

A metanalysis of phase II, III and IV trials in moderate to severe plaque psoriasis suggests comparative efficacy biologic treatments, but that that brodalumab, guselkumab, ixekizumab, and risankizumab-rzaa were shown to have the past skin (PASI) response rates.

The meta-analysis

Read Article

RheumNow Podcast- A Good First Impression (1.24.20)

Jan 24, 2020

Dr Jack Cush comments on this week's journal articles, reviews and studies.

Read Article
×